TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12197588

Group type: EXPERIMENTAL
Intervention: Active teaching methods in health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 0
Study: 9704181

Group type: EXPERIMENTAL
Intervention: Dermofilm (topical preparation)
Number of subjects: 50
Study: 7818622

Group type: EXPERIMENTAL
Intervention: Acadesine high-dose infusion
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Acadesine low-dose infusion
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 116
Study: 2698947

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg twice a day for 2 weeks; 40 mg twice a day for 6 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 17
Study: 1099490

Group type: EXPERIMENTAL
Intervention: Urinary antiseptics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31796521

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Independent review
Number of subjects: 55
Study: 31318603

Group type: EXPERIMENTAL
Intervention: Informational video messaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testimonial video messaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blended video messaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video messaging (combined)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical comparison group (no video messaging)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blended and informational messaging
Number of subjects: 0
Study: 28442186

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Attention-matched control training intervention
Number of subjects: 21
Study: 27328489

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (Gestrinone)
Number of subjects: 157
Study: 24596005

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate and 2 mg dienogest
Number of subjects: 73

Group type: COMPARATOR
Intervention: 2 mg estradiol valerate and 10 mg medroxyprogesterone acetate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Comparison between dienogest and medroxyprogesterone acetate
Number of subjects: 73
Study: 22585765

Group type: EXPERIMENTAL
Intervention: O3FA
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 19454879

Group type: EXPERIMENTAL
Intervention: Press needle (n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (n=45)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Press needle
Number of subjects: 90
Study: 17444886

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 108

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 108
Study: 16094020

Group type: EXPERIMENTAL
Intervention: Rectus fascia sling
Number of subjects: 53

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 53
Study: 12100094

Group type: COMPARATOR
Intervention: 10 mg rizatriptan
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 10 mg rizatriptan plus 25 mg rofecoxib
Number of subjects: 56
Study: 10201675

Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic block
Number of subjects: 36

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 7553241

Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray with benzalkonium chloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxymetazoline nasal spray without benzalkonium chloride
Number of subjects: 20
Study: 2184635

Group type: EXPERIMENTAL
Intervention: Manual anastomosis with monolayer polyglactin 910 sutures
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mechanical anastomosis with E.E.A. stapler
Number of subjects: 48
Study: 7008367

Group type: EXPERIMENTAL
Intervention: Silymarin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31701699

Group type: EXPERIMENTAL
Intervention: γ-linolenic acid (GLA) 320 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: α-lipoic acid (ALA) 600 mg/day
Number of subjects: 100
Study: 31264032

Group type: EXPERIMENTAL
Intervention: Flare management intervention guided by non-physician providers
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 150
Study: 28643377

Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) intervention with home visits and tailored text message reminders
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CHWs support
Number of subjects: 28
Study: 25748566

Group type: EXPERIMENTAL
Intervention: Nebulized pentoxifylline (20 mg/kg every 6 hours for 10 days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (normal saline, equal volume every 6 hours for 10 days)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups (pentoxifylline and placebo)
Number of subjects: 81
Study: 24218465

Group type: EXPERIMENTAL
Intervention: Limited oxygen strategy (LOX)
Number of subjects: 88

Group type: COMPARATOR
Intervention: High oxygen strategy (HOX)
Number of subjects: 88
Study: 22321931

Group type: EXPERIMENTAL
Intervention: FICB with ropivacaine 0.2%, 1 ml/kg, max. 30 ml
Number of subjects: 64

Group type: COMPARATOR
Intervention: FICB with 0.9% normal saline 1 ml/kg, max. 30 ml
Number of subjects: 64
Study: 19390463

Group type: EXPERIMENTAL
Intervention: Intravaginal estriol (1 mg) and progesterone (30 mg) suppositories
Number of subjects: 19
Study: 16318995

Group type: EXPERIMENTAL
Intervention: Externally induced acute pain
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 8
Study: 15636225

Group type: EXPERIMENTAL
Intervention: Plasma homocysteine levels in AMD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma vitamin B12 concentration in AMD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Red blood cell folic acid concentration in AMD patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma folic acid concentration in AMD patients
Number of subjects: 30
Study: 10615231

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 micrograms/day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Nystatin (6,000,000 IU/day)
Number of subjects: 109
Study: 7898595

Group type: EXPERIMENTAL
Intervention: Exercise and weight loss
Number of subjects: 0
Study: 2383027

Group type: EXPERIMENTAL
Intervention: Intralesional sustained release interferon alfa‐2b (10 million IU per injection) - 3 injections
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intralesional sustained release interferon alfa‐2b (10 million IU per injection) - 1 injection
Number of subjects: 65
Study: 6894277

Group type: COMPARATOR
Intervention: Placebo phase of a randomised double blind ergometry study
Number of subjects: 10
Study: 31163231

Group type: EXPERIMENTAL
Intervention: FMX101 4% topical minocycline foam
Number of subjects: 1488

Group type: COMPARATOR
Intervention: Foam vehicle (control)
Number of subjects: 1488
Study: 29935326

Group type: EXPERIMENTAL
Intervention: i-scan 1 (surface and contrast enhancement)
Number of subjects: 740

Group type: COMPARATOR
Intervention: HDWL colonoscopy
Number of subjects: 740
Study: 28160190

Group type: EXPERIMENTAL
Intervention: CKD-712 160 µg/kg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CKD-712 320 µg/kg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CKD-712 (20 to 240 µg/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 24923535

Group type: EXPERIMENTAL
Intervention: Inclined stool (20°)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Flat stool
Number of subjects: 2
Study: 22842478

Group type: EXPERIMENTAL
Intervention: IMA901
Number of subjects: 96

Group type: COMPARATOR
Intervention: Single dose of cyclophosphamide
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Myeloid-derived suppressor cells
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Apolipoprotein A‐I (APOA1) and chemokine (C‐C motif) ligand 17 (CCL17)
Number of subjects: 96
Study: 20732868

Group type: EXPERIMENTAL
Intervention: Relaxin (four doses)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 16690006

Group type: EXPERIMENTAL
Intervention: Low dose venlafaxine (75 mg/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High dose venlafaxine (up to 375 mg/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both low and high doses of venlafaxine
Number of subjects: 44
Study: 16225720

Group type: EXPERIMENTAL
Intervention: Propofol alone (Group P)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Propofol with midazolam 0.1 mg kg(‐1) (Group PM)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl 1 mug kg‐1 (Group PF)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Propofol with midazolam (Group PM)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl (Group PF)
Number of subjects: 240
Study: 12400430

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 216

Group type: COMPARATOR
Intervention: Sham acupressure (placebo)
Number of subjects: 216
Study: 10420139

Group type: EXPERIMENTAL
Intervention: Prolonged occlusion for 24, 48, 72, and 96 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no occlusion)
Number of subjects: 12
Study: 8523658

Group type: EXPERIMENTAL
Intervention: Deeply anesthetized extubation group (anesthetized group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Awake extubation group (awake group)
Number of subjects: 30
Study: 2246304

Group type: EXPERIMENTAL
Intervention: Closed suction drains
Number of subjects: 70

Group type: COMPARATOR
Intervention: No drains (control)
Number of subjects: 70
Study: 6124087

Group type: EXPERIMENTAL
Intervention: Infra-red stimulation using IRS Medtec 100
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mock TNS (placebo)
Number of subjects: 26
Study: 31863040

Group type: EXPERIMENTAL
Intervention: Recommendation of root canal treatment for White patients (86.21%)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Recommendation of extraction for Black patients (60.71%)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: BIAT scores indicating implicit racial bias
Number of subjects: 57
Study: 28862883

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: VR-CHOP (R-CHOP + bortezomib 1.3 mg/m2 on days 1 and 4)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: VR-CHOP
Number of subjects: 206
Study: 26150019

Group type: EXPERIMENTAL
Intervention: 5000 step goal
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 10,000 step goal
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Switch from 5000 to 10,000 steps
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Switch from 10,000 to 5000 steps
Number of subjects: 94
Study: 24444988

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/hr of ketamine and 2 mg/kg/hr of propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 60
Study: 23646099

Group type: EXPERIMENTAL
Intervention: 200 mg LD-¹³C with randomized CD doses (0, 25, 50, 100 and 200 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200 mg LD-¹³C with increasing CD doses
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200 mg LD-¹³C
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LD-breath test
Number of subjects: 6
Study: 19356374

Group type: EXPERIMENTAL
Intervention: Oxymetholone 50 mg orally twice daily for 24 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo twice daily for 24 weeks
Number of subjects: 44
Study: 18080043

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) treatment (400 microT), twice-daily 40 min treatments over seven days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 32
Study: 16805716

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (high doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less intensive statin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins (general)
Number of subjects: 0
Study: 15242434

Group type: EXPERIMENTAL
Intervention: Double injection of 15 ml of 0.75% ropivacaine to each sciatic nerve component (total 30 ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single injection of 30 ml of 0.75% ropivacaine to the sciatic nerve
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single injection
Number of subjects: 50
Study: 10914438

Group type: EXPERIMENTAL
Intervention: Limited excision and open wound healing (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Excision and primary suture (group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Excision and open wound healing (group A)
Number of subjects: 100
Study: 8620641

Group type: EXPERIMENTAL
Intervention: Surgical treatment (primary repair plus early controlled mobilization)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Functional treatment (early controlled mobilization alone)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Functional treatment
Number of subjects: 60
Study: 1627756

Group type: EXPERIMENTAL
Intervention: Potassium chloride (120 mmol/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6518782

Group type: EXPERIMENTAL
Intervention: Marker methodology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current methodology
Number of subjects: 0
Study: 30897499

Group type: EXPERIMENTAL
Intervention: Family interactions around food (less positive)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Family expressiveness (more)
Number of subjects: 162
Study: 28899910

Group type: EXPERIMENTAL
Intervention: 8 hours of hyperoxia (end‐tidal PO2 = 420 mmHg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 8 hours of euoxia (end‐tidal PO2 = 100 mmHg)
Number of subjects: 11
Study: 26594944

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT) and Interpersonal psychotherapy (IPT)
Number of subjects: 85
Study: 25057969

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior constructs (attitude, subjective norm, perceived behavioral control)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Intent to abstain from smoking (predicted by TPB)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Perceived Behavioral Control (PBC)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: TPB constructs (attitude and PBC)
Number of subjects: 169
Study: 23108941

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual-care program
Number of subjects: 75
Study: 19577636

Group type: EXPERIMENTAL
Intervention: Subvirion avian influenza A/H5N1 vaccine with aluminum hydroxide (AlOH)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Subvirion avian influenza A/H5N1 vaccine without aluminum hydroxide (AlOH)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Subvirion avian influenza A/H5N1 vaccine (all doses)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Subvirion avian influenza A/H5N1 vaccine (45microg HA)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Subvirion avian influenza A/H5N1 vaccine (45microg HA with AlOH)
Number of subjects: 600
Study: 17216334

Group type: EXPERIMENTAL
Intervention: Adapted HIV prevention intervention for psychiatric patients in Brazil
Number of subjects: 0
Study: 15204280

Group type: EXPERIMENTAL
Intervention: Upward loading with different load magnitudes (250, 750, and 1250 g) during five- and three-digit grasps.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Downward loading with different load magnitudes (250, 750, and 1250 g) during five- and three-digit grasps.
Number of subjects: 0
Study: 11579363

Group type: EXPERIMENTAL
Intervention: Captopril monotherapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Carvedilol monotherapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined treatment (Captopril + Carvedilol)
Number of subjects: 57
Study: 9795022

Group type: EXPERIMENTAL
Intervention: Rectal suppository
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All routes
Number of subjects: 0
Study: 7986489

Group type: EXPERIMENTAL
Intervention: D-cycloserine (25 to 500 mg daily, dose escalation phase)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2929903

Group type: EXPERIMENTAL
Intervention: Lignocaine 1 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lignocaine 2 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 80
Study: 30623490

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 284
Study: 27943397

Group type: EXPERIMENTAL
Intervention: Thiopurine treatment with 6-MMP concentrations measured at T1 (1 week after treatment initiation)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Patients exceeding the 6-MMP threshold of 3615 pmol/8 × 108 erythrocytes
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Patients with 6-MMP concentrations above the threshold
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Predictive algorithm based on 6-MMP threshold and risk factors (age, gender, BMI)
Number of subjects: 270
Study: 25524249

Group type: EXPERIMENTAL
Intervention: Media Smart
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1316
Study: 24089534

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 3862

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 3862

Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP and hs-cTnT
Number of subjects: 3862
Study: 21122848

Group type: EXPERIMENTAL
Intervention: 600‐μg oral misoprostol
Number of subjects: 230

Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 230
Study: 18817930

Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17530457

Group type: EXPERIMENTAL
Intervention: dimenhydrinate (100 mg)
Number of subjects: 16
Study: 15468399

Group type: EXPERIMENTAL
Intervention: Topical negative pressure dressing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard bolster dressing
Number of subjects: 20
Study: 11854606

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 500 mg b.i.d. for a mean of 12.5 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 12
Study: 10510161

Group type: COMPARATOR
Intervention: Digoxin alone (0.5 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Digoxin with macrogol 4000 (20 g day-1 for 8 days)
Number of subjects: 18
Study: 7737960

Group type: EXPERIMENTAL
Intervention: Adinazolam-SR 60 mg/day
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Adinazolam-SR 90 mg/day
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Adinazolam-SR 30 mg/day
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 1970300

Group type: EXPERIMENTAL
Intervention: bopindolol 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 0
Study: 7359503

Group type: EXPERIMENTAL
Intervention: DES-exposed group
Number of subjects: 429
Study: 30853250

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (50 mg/kg once daily) at home
Number of subjects: 190

Group type: COMPARATOR
Intervention: Intravenous flucloxacillin (50 mg/kg every 6 h) in hospital
Number of subjects: 190
Study: 25852972

Group type: EXPERIMENTAL
Intervention: Facebook-based intervention (FITNET)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Facebook-based self-help comparison group
Number of subjects: 86
Study: 24946799

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (30 sessions)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual physical therapy (30 sessions)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (Experimental and Control)
Number of subjects: 53
Study: 23002124

Group type: EXPERIMENTAL
Intervention: PEG‐IFN (peginterferon alfa‐2b), 6 μg/kg per week for eight doses, followed by 3 μg/kg per week for up to 252 weeks
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: PEG‐IFN (peginterferon alfa‐2b)
Number of subjects: 1256
Study: 19735181

Group type: EXPERIMENTAL
Intervention: 2 g n-3 PUFAs
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 0.5 g n-3 PUFAs
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 1 g n-3 PUFAs
Number of subjects: 132
Study: 17697343

Group type: EXPERIMENTAL
Intervention: Planned vaginal birth after caesarean
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Planned elective repeat caesarean
Number of subjects: 2314
Study: 15260837

Group type: EXPERIMENTAL
Intervention: Agricultural Disability Awareness and Risk Education (AgDARE) curriculum
Number of subjects: 2000000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2000000
Study: 11432030

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (Copaxone ‐ Teva)
Number of subjects: 0
Study: 9007484

Group type: EXPERIMENTAL
Intervention: Tetanus-PRP conjugate vaccine
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: DTPa-HBV components
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Unconjugated PRP
Number of subjects: 369